This high-risk group includes patients with high-grade papillary stage Ta or T1 tumors and any patient with carcinoma in situ (CIS), and makes up 15–44% of patients with non-muscle-invasive ...

Aggressive Digital Papillary Adenocarcinoma (DPA ... For instance, a study utilizing in situ hybridization found that all examined DPA tumors tested positive for HPV42, while other sweat gland ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors.

with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer. According to the Centers for Disease Control and Prevention, about 57,000 ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

patients with carcinoma in situ (CIS), with or without papillary tumors. Acceptance of ImmunityBio’s applications seeking approval of the combo therapy by respective regulatory bodies in the EU ...

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...